Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci
Abstract Background Evidence supporting combination treatment with a beta-lactam plus an aminoglycoside (C-BA) for endocarditis caused by viridans and gallolyticus group streptococci (VGS-GGS) with intermediate susceptibility to penicillin (PENI-I) is lacking. We assessed the clinical characteristic...
Gespeichert in:
Veröffentlicht in: | Clinical infectious diseases 2023-11, Vol.77 (9), p.1273-1281 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1281 |
---|---|
container_issue | 9 |
container_start_page | 1273 |
container_title | Clinical infectious diseases |
container_volume | 77 |
creator | Escrihuela-Vidal, Francesc Berbel, Damaris Fernández-Hidalgo, Núria Escolà-Vergé, Laura Muñoz, Patricia Olmedo, María Goenaga, Miguel Ángel Goikoetxea, Josune Fariñas, María Carmen De Alarcón, Arístides Miró, José M Ojeda, Guillermo Plata, Antonio Cuervo, Guillermo Carratalà, Jordi |
description | Abstract
Background
Evidence supporting combination treatment with a beta-lactam plus an aminoglycoside (C-BA) for endocarditis caused by viridans and gallolyticus group streptococci (VGS-GGS) with intermediate susceptibility to penicillin (PENI-I) is lacking. We assessed the clinical characteristics and outcomes of PEN-I VGS-GGS endocarditis and compared the effectiveness and safety of C-BA with third-generation cephalosporin monotherapy.
Methods
Retrospective analysis of prospectively collected data of a cohort of definite endocarditis caused by penicillin-susceptible and PENI-I VGS-GGS (penicillin minimum inhibitory concentration ranging from 0.25 to 2 mg/L) between 2008 and 2018 in 40 Spanish hospitals. We compared cases treated with monotherapy or with C-BA and performed multivariable analyses of risk factors for in-hospital and 1-year mortality.
Results
A total of 914 consecutive cases of definite endocarditis caused by VGS-GGS with complete or intermediate susceptibility to penicillin were included. A total of 688 (75.3%) were susceptible to penicillin and 226 (24.7%) were PENI-I. Monotherapy was used in 415 (45.4%) cases (cephalosporin in 331 cases) and 499 (54.6%) cases received C-BA. In-hospital mortality was 11.9%, and 190 (20.9%) patients developed acute kidney injury. Heart failure (odds ratio [OR]: 6.06; 95% confidence interval [CI]: 1.37–26.87; P = .018), central nervous system emboli (OR: 9.83; 95% CI: 2.17–44.49; P = .003) and intracardiac abscess (OR: 13.47; 95% CI: 2.24–81.08; P = .004) were independently associated with in-hospital mortality among PEN-I VGS-GGS cases, while monotherapy was not (OR: 1.01; 95% CI: .26–3.96; P = .982).
Conclusions
Our findings support the use of cephalosporin monotherapy in PEN-I VGS-GGS endocarditis in order to avoid nephrotoxicity without adversely affecting patient outcomes.
In a retrospective analysis of endocarditis due to viridans and gallolyticus groups streptococci, cephalosporin monotherapy was not associated with higher in-hospital mortality when the isolate showed intermediate susceptibility to penicillin. |
doi_str_mv | 10.1093/cid/ciad375 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2828759264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciad375</oup_id><sourcerecordid>2828759264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-650da51c922b52da863d2f8d27dab479b163e9f5ece308c780feb159c303cf143</originalsourceid><addsrcrecordid>eNp9kUtrHDEQhEWIiR_JKfegUwiEjfVYzWiOZnHWCwYbbOc6aFoa6KCRJpLmsH_HvzTa7CbHHJruw0c1VUXIR86-cdbJa0Bbx1jZqjfkgivZrhrV8bf1Zkqv1lrqc3KZ80_GONdMvSPnspVrpZvugrzuptlAoXGku1BcmpxFUxx9WjK4ueCAHsuelkgfXUBA7zHQGOhNKDghpDig8fQ5OVMmFwo1wdKHpUCcXD6I3gYbwSSLBTPdmCU7S4c9_YEJrQn5D7813ke_LwhLptsUl5k-lVS_R4gA-J6cjcZn9-G0r8jL99vnzd3q_mG729zcr0AKVqpnZo3i0AkxKGGNbqQVo7aitWZYt93AG-m6UTlwkmloNRvdwFUHkkkY-VpekS9H3TnFX4vLpZ-whuC9CS4uuRda6FZ1ojmgX49oDSDn5MZ-TjiZtO856w-l9LWU_lRKpT-dhJeh5vuP_dtCBT4fgWr9v0q_ATnfmfE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2828759264</pqid></control><display><type>article</type><title>Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>Oxford Journals</source><creator>Escrihuela-Vidal, Francesc ; Berbel, Damaris ; Fernández-Hidalgo, Núria ; Escolà-Vergé, Laura ; Muñoz, Patricia ; Olmedo, María ; Goenaga, Miguel Ángel ; Goikoetxea, Josune ; Fariñas, María Carmen ; De Alarcón, Arístides ; Miró, José M ; Ojeda, Guillermo ; Plata, Antonio ; Cuervo, Guillermo ; Carratalà, Jordi</creator><creatorcontrib>Escrihuela-Vidal, Francesc ; Berbel, Damaris ; Fernández-Hidalgo, Núria ; Escolà-Vergé, Laura ; Muñoz, Patricia ; Olmedo, María ; Goenaga, Miguel Ángel ; Goikoetxea, Josune ; Fariñas, María Carmen ; De Alarcón, Arístides ; Miró, José M ; Ojeda, Guillermo ; Plata, Antonio ; Cuervo, Guillermo ; Carratalà, Jordi ; GAMES investigators ; for the GAMES Investigators</creatorcontrib><description>Abstract
Background
Evidence supporting combination treatment with a beta-lactam plus an aminoglycoside (C-BA) for endocarditis caused by viridans and gallolyticus group streptococci (VGS-GGS) with intermediate susceptibility to penicillin (PENI-I) is lacking. We assessed the clinical characteristics and outcomes of PEN-I VGS-GGS endocarditis and compared the effectiveness and safety of C-BA with third-generation cephalosporin monotherapy.
Methods
Retrospective analysis of prospectively collected data of a cohort of definite endocarditis caused by penicillin-susceptible and PENI-I VGS-GGS (penicillin minimum inhibitory concentration ranging from 0.25 to 2 mg/L) between 2008 and 2018 in 40 Spanish hospitals. We compared cases treated with monotherapy or with C-BA and performed multivariable analyses of risk factors for in-hospital and 1-year mortality.
Results
A total of 914 consecutive cases of definite endocarditis caused by VGS-GGS with complete or intermediate susceptibility to penicillin were included. A total of 688 (75.3%) were susceptible to penicillin and 226 (24.7%) were PENI-I. Monotherapy was used in 415 (45.4%) cases (cephalosporin in 331 cases) and 499 (54.6%) cases received C-BA. In-hospital mortality was 11.9%, and 190 (20.9%) patients developed acute kidney injury. Heart failure (odds ratio [OR]: 6.06; 95% confidence interval [CI]: 1.37–26.87; P = .018), central nervous system emboli (OR: 9.83; 95% CI: 2.17–44.49; P = .003) and intracardiac abscess (OR: 13.47; 95% CI: 2.24–81.08; P = .004) were independently associated with in-hospital mortality among PEN-I VGS-GGS cases, while monotherapy was not (OR: 1.01; 95% CI: .26–3.96; P = .982).
Conclusions
Our findings support the use of cephalosporin monotherapy in PEN-I VGS-GGS endocarditis in order to avoid nephrotoxicity without adversely affecting patient outcomes.
In a retrospective analysis of endocarditis due to viridans and gallolyticus groups streptococci, cephalosporin monotherapy was not associated with higher in-hospital mortality when the isolate showed intermediate susceptibility to penicillin.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciad375</identifier><identifier>PMID: 37345869</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Clinical infectious diseases, 2023-11, Vol.77 (9), p.1273-1281</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-650da51c922b52da863d2f8d27dab479b163e9f5ece308c780feb159c303cf143</citedby><cites>FETCH-LOGICAL-c320t-650da51c922b52da863d2f8d27dab479b163e9f5ece308c780feb159c303cf143</cites><orcidid>0000-0002-7075-943X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37345869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Escrihuela-Vidal, Francesc</creatorcontrib><creatorcontrib>Berbel, Damaris</creatorcontrib><creatorcontrib>Fernández-Hidalgo, Núria</creatorcontrib><creatorcontrib>Escolà-Vergé, Laura</creatorcontrib><creatorcontrib>Muñoz, Patricia</creatorcontrib><creatorcontrib>Olmedo, María</creatorcontrib><creatorcontrib>Goenaga, Miguel Ángel</creatorcontrib><creatorcontrib>Goikoetxea, Josune</creatorcontrib><creatorcontrib>Fariñas, María Carmen</creatorcontrib><creatorcontrib>De Alarcón, Arístides</creatorcontrib><creatorcontrib>Miró, José M</creatorcontrib><creatorcontrib>Ojeda, Guillermo</creatorcontrib><creatorcontrib>Plata, Antonio</creatorcontrib><creatorcontrib>Cuervo, Guillermo</creatorcontrib><creatorcontrib>Carratalà, Jordi</creatorcontrib><creatorcontrib>GAMES investigators</creatorcontrib><creatorcontrib>for the GAMES Investigators</creatorcontrib><title>Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
Background
Evidence supporting combination treatment with a beta-lactam plus an aminoglycoside (C-BA) for endocarditis caused by viridans and gallolyticus group streptococci (VGS-GGS) with intermediate susceptibility to penicillin (PENI-I) is lacking. We assessed the clinical characteristics and outcomes of PEN-I VGS-GGS endocarditis and compared the effectiveness and safety of C-BA with third-generation cephalosporin monotherapy.
Methods
Retrospective analysis of prospectively collected data of a cohort of definite endocarditis caused by penicillin-susceptible and PENI-I VGS-GGS (penicillin minimum inhibitory concentration ranging from 0.25 to 2 mg/L) between 2008 and 2018 in 40 Spanish hospitals. We compared cases treated with monotherapy or with C-BA and performed multivariable analyses of risk factors for in-hospital and 1-year mortality.
Results
A total of 914 consecutive cases of definite endocarditis caused by VGS-GGS with complete or intermediate susceptibility to penicillin were included. A total of 688 (75.3%) were susceptible to penicillin and 226 (24.7%) were PENI-I. Monotherapy was used in 415 (45.4%) cases (cephalosporin in 331 cases) and 499 (54.6%) cases received C-BA. In-hospital mortality was 11.9%, and 190 (20.9%) patients developed acute kidney injury. Heart failure (odds ratio [OR]: 6.06; 95% confidence interval [CI]: 1.37–26.87; P = .018), central nervous system emboli (OR: 9.83; 95% CI: 2.17–44.49; P = .003) and intracardiac abscess (OR: 13.47; 95% CI: 2.24–81.08; P = .004) were independently associated with in-hospital mortality among PEN-I VGS-GGS cases, while monotherapy was not (OR: 1.01; 95% CI: .26–3.96; P = .982).
Conclusions
Our findings support the use of cephalosporin monotherapy in PEN-I VGS-GGS endocarditis in order to avoid nephrotoxicity without adversely affecting patient outcomes.
In a retrospective analysis of endocarditis due to viridans and gallolyticus groups streptococci, cephalosporin monotherapy was not associated with higher in-hospital mortality when the isolate showed intermediate susceptibility to penicillin.</description><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kUtrHDEQhEWIiR_JKfegUwiEjfVYzWiOZnHWCwYbbOc6aFoa6KCRJpLmsH_HvzTa7CbHHJruw0c1VUXIR86-cdbJa0Bbx1jZqjfkgivZrhrV8bf1Zkqv1lrqc3KZ80_GONdMvSPnspVrpZvugrzuptlAoXGku1BcmpxFUxx9WjK4ueCAHsuelkgfXUBA7zHQGOhNKDghpDig8fQ5OVMmFwo1wdKHpUCcXD6I3gYbwSSLBTPdmCU7S4c9_YEJrQn5D7813ke_LwhLptsUl5k-lVS_R4gA-J6cjcZn9-G0r8jL99vnzd3q_mG729zcr0AKVqpnZo3i0AkxKGGNbqQVo7aitWZYt93AG-m6UTlwkmloNRvdwFUHkkkY-VpekS9H3TnFX4vLpZ-whuC9CS4uuRda6FZ1ojmgX49oDSDn5MZ-TjiZtO856w-l9LWU_lRKpT-dhJeh5vuP_dtCBT4fgWr9v0q_ATnfmfE</recordid><startdate>20231111</startdate><enddate>20231111</enddate><creator>Escrihuela-Vidal, Francesc</creator><creator>Berbel, Damaris</creator><creator>Fernández-Hidalgo, Núria</creator><creator>Escolà-Vergé, Laura</creator><creator>Muñoz, Patricia</creator><creator>Olmedo, María</creator><creator>Goenaga, Miguel Ángel</creator><creator>Goikoetxea, Josune</creator><creator>Fariñas, María Carmen</creator><creator>De Alarcón, Arístides</creator><creator>Miró, José M</creator><creator>Ojeda, Guillermo</creator><creator>Plata, Antonio</creator><creator>Cuervo, Guillermo</creator><creator>Carratalà, Jordi</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7075-943X</orcidid></search><sort><creationdate>20231111</creationdate><title>Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci</title><author>Escrihuela-Vidal, Francesc ; Berbel, Damaris ; Fernández-Hidalgo, Núria ; Escolà-Vergé, Laura ; Muñoz, Patricia ; Olmedo, María ; Goenaga, Miguel Ángel ; Goikoetxea, Josune ; Fariñas, María Carmen ; De Alarcón, Arístides ; Miró, José M ; Ojeda, Guillermo ; Plata, Antonio ; Cuervo, Guillermo ; Carratalà, Jordi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-650da51c922b52da863d2f8d27dab479b163e9f5ece308c780feb159c303cf143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Escrihuela-Vidal, Francesc</creatorcontrib><creatorcontrib>Berbel, Damaris</creatorcontrib><creatorcontrib>Fernández-Hidalgo, Núria</creatorcontrib><creatorcontrib>Escolà-Vergé, Laura</creatorcontrib><creatorcontrib>Muñoz, Patricia</creatorcontrib><creatorcontrib>Olmedo, María</creatorcontrib><creatorcontrib>Goenaga, Miguel Ángel</creatorcontrib><creatorcontrib>Goikoetxea, Josune</creatorcontrib><creatorcontrib>Fariñas, María Carmen</creatorcontrib><creatorcontrib>De Alarcón, Arístides</creatorcontrib><creatorcontrib>Miró, José M</creatorcontrib><creatorcontrib>Ojeda, Guillermo</creatorcontrib><creatorcontrib>Plata, Antonio</creatorcontrib><creatorcontrib>Cuervo, Guillermo</creatorcontrib><creatorcontrib>Carratalà, Jordi</creatorcontrib><creatorcontrib>GAMES investigators</creatorcontrib><creatorcontrib>for the GAMES Investigators</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Escrihuela-Vidal, Francesc</au><au>Berbel, Damaris</au><au>Fernández-Hidalgo, Núria</au><au>Escolà-Vergé, Laura</au><au>Muñoz, Patricia</au><au>Olmedo, María</au><au>Goenaga, Miguel Ángel</au><au>Goikoetxea, Josune</au><au>Fariñas, María Carmen</au><au>De Alarcón, Arístides</au><au>Miró, José M</au><au>Ojeda, Guillermo</au><au>Plata, Antonio</au><au>Cuervo, Guillermo</au><au>Carratalà, Jordi</au><aucorp>GAMES investigators</aucorp><aucorp>for the GAMES Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2023-11-11</date><risdate>2023</risdate><volume>77</volume><issue>9</issue><spage>1273</spage><epage>1281</epage><pages>1273-1281</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
Background
Evidence supporting combination treatment with a beta-lactam plus an aminoglycoside (C-BA) for endocarditis caused by viridans and gallolyticus group streptococci (VGS-GGS) with intermediate susceptibility to penicillin (PENI-I) is lacking. We assessed the clinical characteristics and outcomes of PEN-I VGS-GGS endocarditis and compared the effectiveness and safety of C-BA with third-generation cephalosporin monotherapy.
Methods
Retrospective analysis of prospectively collected data of a cohort of definite endocarditis caused by penicillin-susceptible and PENI-I VGS-GGS (penicillin minimum inhibitory concentration ranging from 0.25 to 2 mg/L) between 2008 and 2018 in 40 Spanish hospitals. We compared cases treated with monotherapy or with C-BA and performed multivariable analyses of risk factors for in-hospital and 1-year mortality.
Results
A total of 914 consecutive cases of definite endocarditis caused by VGS-GGS with complete or intermediate susceptibility to penicillin were included. A total of 688 (75.3%) were susceptible to penicillin and 226 (24.7%) were PENI-I. Monotherapy was used in 415 (45.4%) cases (cephalosporin in 331 cases) and 499 (54.6%) cases received C-BA. In-hospital mortality was 11.9%, and 190 (20.9%) patients developed acute kidney injury. Heart failure (odds ratio [OR]: 6.06; 95% confidence interval [CI]: 1.37–26.87; P = .018), central nervous system emboli (OR: 9.83; 95% CI: 2.17–44.49; P = .003) and intracardiac abscess (OR: 13.47; 95% CI: 2.24–81.08; P = .004) were independently associated with in-hospital mortality among PEN-I VGS-GGS cases, while monotherapy was not (OR: 1.01; 95% CI: .26–3.96; P = .982).
Conclusions
Our findings support the use of cephalosporin monotherapy in PEN-I VGS-GGS endocarditis in order to avoid nephrotoxicity without adversely affecting patient outcomes.
In a retrospective analysis of endocarditis due to viridans and gallolyticus groups streptococci, cephalosporin monotherapy was not associated with higher in-hospital mortality when the isolate showed intermediate susceptibility to penicillin.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37345869</pmid><doi>10.1093/cid/ciad375</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7075-943X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2023-11, Vol.77 (9), p.1273-1281 |
issn | 1058-4838 1537-6591 |
language | eng |
recordid | cdi_proquest_miscellaneous_2828759264 |
source | Alma/SFX Local Collection; EZB Electronic Journals Library; Oxford Journals |
title | Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T09%3A52%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Intermediate%20Susceptibility%20to%20Penicillin%20on%20Antimicrobial%20Treatment%20and%20Outcomes%20of%20Endocarditis%20Caused%20by%20Viridans%20and%20Gallolyticus%20Group%20Streptococci&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Escrihuela-Vidal,%20Francesc&rft.aucorp=GAMES%20investigators&rft.date=2023-11-11&rft.volume=77&rft.issue=9&rft.spage=1273&rft.epage=1281&rft.pages=1273-1281&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciad375&rft_dat=%3Cproquest_cross%3E2828759264%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2828759264&rft_id=info:pmid/37345869&rft_oup_id=10.1093/cid/ciad375&rfr_iscdi=true |